## PATENT APPLICATION SERIAL NO. 09/936499

## U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FEE RECORD SHEET

09/18/2001 MKAYPAGH 00000115 501293 09936499

01 FC:962 02 FC:154

100.00 CH 130.00 CH

PTO-1556 (5/87)

\*U.S. GPO: 2000-468-987/39595

533 Recapetypto 12 SEP 2001

FORMPTO-1390 (REV 12-29-99) RTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE TRANSMITTAL LETTER TO THE UNITED STATES MWH-0031US DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO. (If known, see 37 CFR 1.5) CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED 12 March 1999 (12.03.99) PCT/US00/06502 10 March 2000 (10.03.00) TITLE OF INVENTION Variation in Drug Response Related to Polymorphisms in Beta 2-Adrenergic Receptor APPLICANT(S) FOR DO/EO/US LIGGETT, Stephen B. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. A substitute specification. A change of power of attorney and/or address letter. Other items or information: Statement regarding Sequence Listing

U.S. APPLICATION NO. (if k CT/US00/06502 **CALCULATIONS** PTO USE ONLY The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00 and International Search Report not prepared by the EPO or JPO · · · · · · · International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ......\$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) ENTER APPROPRIATE BASIC FEE AMOUNT 100.00 Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). 130.00 NUMBER FILED CLAIMS NUMBER EXTRA RATE Total claims 14 X \$18.00 0.00 - 20 = \$ Independent claims 0 0.00 3 X \$78.00 - 3 = \$ MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$260.00 \$ 0.00230.00 TOTAL OF ABOVE CALCULATIONS \$ Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also by filed (Note 37 CFR 1.9, 1.27, 1.28). 0.00230.00 **SUBTOTAL** Processing fee of \$130.00 for furnishing the English translation later than 20 \$ months from the earliest claimed priority date (37 CFR 1.492(f)). 0.00\$ 230.00 TOTAL NATIONAL FEE Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be \$ accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property 0.00230.00 TOTAL FEES ENCLOSED Amount to be refunded: charged: A check in the amount of \$\_\_\_\_\_ to cover the above fees is enclosed. Please charge my Deposit Account No. 50-1293 in the amount of \$230.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1293. A duplicate copy of this sheet is enclosed. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. GWELA M. ()1 ELO SIGNATURE: /) SEND ALL CORRESPONDENCE TO: Gisela M. Field Genaissance Pharmaceuticals, Inc. Gisela M. Field 5 Science Park New Haven, CT 06511 47,562 USA REGISTRATION NUMBER

#518 Recid POT/PTO #1 2 SEP # 2001